@prefix : <http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#> .
@prefix mp: <http://purl.org/mp/> .
@prefix oa: <http://www.w3.org/ns/oa#> .
@prefix opv: <http://inab.certh.gr/OpenPVSignal> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xml: <http://www.w3.org/XML/1998/namespace> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix openpvsignal: <http://purl.org/OpenPVSignal/OpenPVSignal.owl> .
@base <http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl> .

<http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl> rdf:type owl:Ontology ;
                                                                          owl:imports <http://purl.org/OpenPVSignal/OpenPVSignal.owl> ;
                                                                          rdfs:isDefinedBy "https://apps.who.int/iris/handle/10665/311036/"^^xsd:anyURI ;
                                                                          rdfs:label "Levofloxacin and myoclonus in the elderly over 75 years: susceptibilities and prescribing issues"^^rdfs:Literal ;
                                                                          owl:versionInfo "draft-v0.95-20210520"@en .

#################################################################
#    Object Properties
#################################################################

###  http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element
<http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element> rdf:type owl:ObjectProperty .


###  http://purl.org/mp/publishedBy
mp:publishedBy rdf:type owl:ObjectProperty .


###  http://purl.org/mp/references
mp:references rdf:type owl:ObjectProperty .


###  http://purl.org/mp/supportedByData
mp:supportedByData rdf:type owl:ObjectProperty .


#################################################################
#    Data properties
#################################################################

###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#concerns_action_upon_adverse_effect
:concerns_action_upon_adverse_effect rdf:type owl:DatatypeProperty .


###  http://purl.org/mp/citation
mp:citation rdf:type owl:DatatypeProperty .


#################################################################
#    Classes
#################################################################

###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#conclusion
:conclusion rdf:type owl:Class .


###  http://www.w3.org/ns/prov#Organization
<http://www.w3.org/ns/prov#Organization> rdf:type owl:Class .


#################################################################
#    Individuals
#################################################################

###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#AcetylsalicylicAcid
:AcetylsalicylicAcid rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A01AD05" ,
                                                                                  "B01AC06" ,
                                                                                  "B01AC56" ,
                                                                                  "C10BX01" ,
                                                                                  "C10BX02" ,
                                                                                  "C10BX04" ,
                                                                                  "C10BX05" ,
                                                                                  "C10BX06" ,
                                                                                  "C10BX08" ,
                                                                                  "M01BA03" ,
                                                                                  "N02BA01" ,
                                                                                  "N02BA51" ,
                                                                                  "N02BA71" ;
                     rdfs:label "Acetylsalicylic acid" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Acute_bronchitis
:Acute_bronchitis rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "J20. 9" ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10000687 ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Acute bronchitis" ;
                  rdfs:label "Acute bronchitis" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Alfuzosin
:Alfuzosin rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "G04CA01" ,
                                                                        "G04CA51" ;
           rdfs:label "Alfuzosin" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Amiodarone
:Amiodarone rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C01BD01" ;
            rdfs:label "Amiodarone" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Atorvastatin
:Atorvastatin rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C10AA05" ,
                                                                           "C10BA05" ,
                                                                           "C10BX03" ,
                                                                           "C10BX06" ,
                                                                           "C10BX08" ,
                                                                           "C10BX11" ;
              rdfs:label "Atorvastatin" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Bicalutamide
:Bicalutamide rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "L02BB03" ;
              rdfs:label "Bicalutamide" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Bisoprolol
:Bisoprolol rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C07AB07" ,
                                                                         "C07AB57" ,
                                                                         "C07BB07" ,
                                                                         "C07FB07" ,
                                                                         "C09BX02" ;
            rdfs:label "Bisoprolol" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#BlackBoxWarningForFluoroquinolones
:BlackBoxWarningForFluoroquinolones rdf:type owl:NamedIndividual ,
                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Warning_Information> ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :fluoroquinolones ;
                                    mp:references :Literature_and_Labelling ;
                                    mp:citation """A recent US FDA Black Box Warning for
fluoroquinolones advises restriction of the use of
these antibiotics in infections for which a choice of
antibiotics is available, because of serious reactions
including CNS effects.1 Dose adjustment in renal
failure, careful review of co-prescriptions and
monitoring of patients with predisposing CNS
conditions should also reduce the possibility of
myoclonus and seizures.""" ;
                                    rdfs:label "Black box Warning for fluoroquinolones" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Bronchitis
:Bronchitis rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "J18. 9" ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10049490 ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Pneumopathy" ;
            rdfs:label "Pneumopathy" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#CNSStimulation
:CNSStimulation rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10061444 ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> """Central nervous system stimulation
""" ;
                rdfs:label "CNS stimulation" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Ceftriaxone
:Ceftriaxone rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "J01DD04" ;
             rdfs:label "Ceftriaxone" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Chorea
:Chorea rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "G25.5" ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10008748 ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Chorea" ;
        rdfs:label "Chorea" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Clopidogrel
:Clopidogrel rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "B01AC04" ;
             rdfs:label "Clopidogrel" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Coma
:Coma rdf:type owl:NamedIndividual ,
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R40.2" ;
      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10010071 ;
      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "	Coma" ;
      rdfs:label "Coma" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#CorticalAtrophy
:CorticalAtrophy rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Potential_Confounder> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "G31.9" ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10008096 ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Cerebral atrophy, 	Posterior cortical atrophy" ;
                 rdfs:label "Cortical atrophy" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Decreasing_the_seizure_threshold
:Decreasing_the_seizure_threshold rdf:type owl:NamedIndividual ,
                                           <http://purl.obolibrary.org/obo/OAE_0001182> ;
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Seizures ;
                                  mp:references :Ref.11 ,
                                                :Ref.9 ;
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Many of these medicines also decrease the seizure threshold.9,11" ;
                                  rdfs:label "Decreasing the seizure threshold" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Dementia
:Dementia rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Potential_Confounder> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "F03.90" ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10012267 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Dementia" ;
          rdfs:label "Dementia" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Digoxin
:Digoxin rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C01AA05" ;
         rdfs:label "Digoxin" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Discussion
:Discussion rdf:type owl:NamedIndividual ,
                     :conclusion ;
            mp:references :Ref.1 ,
                          :Ref.11 ,
                          :Ref.13 ,
                          :Ref.14 ,
                          :Ref.2 ,
                          :Ref.9 ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "We describe a case series of patients aged over 75 years who developed myoclonus within days of starting levofloxacin and often recovered when they discontinued this medicine even when there was continuation of co-morbidities or coprescribed medicines that in themselves could cause myoclonus. It is possible that they had a contributory role in the development of myoclonus. Another potentially contributing factor was renal impairment with little evidence of dose adjustment. While there was evidence of a causal association between levofloxacin and myoclonus in both age groups, renal impairment and co-morbidities that increase CNS sensitivity were present more often in the elderly group. In contrast, co-prescriptions were potential contributors in both the older and younger age groups. Although the product labels indicate that increasing age alone does not increase the risk of levofloxacin-related CNS adverse effects these are more likely to occur in the elderly as renal function diminishes with age, accelerated by some age-related clinical conditions. This decline may not always be detected if serum creatinine is low due to decreased muscle mass. Thus, accurate measurement of renal function and dose adjustment to avoid accumulation of levofloxacin is essential. However, there is discussion about the most appropriate dose adjustment regime to maintain efficacy as well as reduce toxicity.13,14 The level of adjustment is based on the initial recommended dose for the presenting infection and the degree of renal impairment. However, the emphasis on decreasing the dose or increasing the dose interval varies, for example, between the US FDA label1 and the UK SmPC.2 CNS morbidities predisposing to myoclonus also increase with age as do co-prescriptions. However, co-prescribing of medicines that might induce myoclonus was an issue for all age groups. Many of these medicines also decrease the seizure threshold.9,11 and several patients had seizures in this case series. For some patients complex treatment with several medicines, including multiple antibiotics, all of which can lead to myoclonus and seizures, is unavoidable. However, the reports support product label advice to avoid these combinations whenever possible. A recent US FDA Black Box Warning for fluoroquinolones advises restriction of the use of these antibiotics in infections for which a choice of antibiotics is available, because of serious reactions including CNS effects.1 Dose adjustment in renal failure, careful review of co-prescriptions and monitoring of patients with predisposing CNS conditions should also reduce the possibility of myoclonus and seizures." ;
            rdfs:label "Discussion" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Donepezil
:Donepezil rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N06DA02" ;
           rdfs:label "donepezil" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#DoseForPatient1
:DoseForPatient1 rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg" ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 500 ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_process> "true"^^xsd:boolean ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "500 mg " ;
                 rdfs:label "Dose for Patient 1" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#DoseForPatient10
:DoseForPatient10 rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg" ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 1000 ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_process> "true"^^xsd:boolean ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "1000 mg" ;
                  <http://www.w3.org/2006/time#nominalPosition> "days" ;
                  <http://www.w3.org/2006/time#numericDuration> 6 ;
                  rdfs:label "Dose for Patient 10" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#DoseForPatient11
:DoseForPatient11 rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
                  <http://www.w3.org/2006/time#nominalPosition> "days" ;
                  <http://www.w3.org/2006/time#numericDuration> 16 ;
                  rdfs:label "Dose for Patient 11" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#DoseForPatient2
:DoseForPatient2 rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg" ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 750 ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_process> "true"^^xsd:boolean ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "750 mg" ;
                 <http://www.w3.org/2006/time#nominalPosition> "days" ;
                 <http://www.w3.org/2006/time#numericDuration> 9 ;
                 rdfs:label "Dose for Patient 2" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#DoseForPatient3
:DoseForPatient3 rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg" ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 1000 ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "1000 mg" ;
                 <http://www.w3.org/2006/time#nominalPosition> "days" ;
                 <http://www.w3.org/2006/time#numericDuration> 1 ;
                 rdfs:label "Dose 1 for Patient 3" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#DoseForPatient4
:DoseForPatient4 rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg" ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 500 ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_process> "true"^^xsd:boolean ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "500 mg" ;
                 <http://www.w3.org/2006/time#nominalPosition> "days" ;
                 <http://www.w3.org/2006/time#numericDuration> 5 ;
                 rdfs:label "Dose for Patient 4" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#DoseForPatient5
:DoseForPatient5 rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg" ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 500 ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_process> "true"^^xsd:boolean ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "500 mg" ;
                 <http://www.w3.org/2006/time#nominalPosition> "days" ;
                 <http://www.w3.org/2006/time#numericDuration> 3 ;
                 rdfs:label "Dose for Patient 5" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#DoseForPatient6
:DoseForPatient6 rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg" ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 1000 ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_process> "true"^^xsd:boolean ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "1000 mg" ;
                 <http://www.w3.org/2006/time#nominalPosition> "days" ;
                 <http://www.w3.org/2006/time#numericDuration> 7 ;
                 rdfs:label "Dose for Patient 6" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#DoseForPatient7
:DoseForPatient7 rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg" ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 1000 ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_process> "true"^^xsd:boolean ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "1000 mg" ;
                 <http://www.w3.org/2006/time#nominalPosition> "days" ;
                 <http://www.w3.org/2006/time#numericDuration> 7 ;
                 rdfs:label "Dose for Patient 7" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#DoseForPatient8
:DoseForPatient8 rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg" ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 500 ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "500 mg" ;
                 <http://www.w3.org/2006/time#nominalPosition> "days" ;
                 <http://www.w3.org/2006/time#numericDuration> 30 ;
                 rdfs:label "Dose for Patient 8" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#DoseForPatient9
:DoseForPatient9 rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg" ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 500 ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_process> "true"^^xsd:boolean ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "500 mg" ;
                 <http://www.w3.org/2006/time#nominalPosition> "days" ;
                 <http://www.w3.org/2006/time#numericDuration> 5 ;
                 rdfs:label "Dose for Patient 9" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#DoseOfLevofloxacinInUS
:DoseOfLevofloxacinInUS rdf:type owl:NamedIndividual ,
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :levofloxacin_interval_administration ;
                        mp:references :Ref.1 ,
                                      :Ref.2 ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Recommended daily doses range from 250 mg for uncomplicated urinary tract infections to 750 mg for more serious diverse bacterial infections according to the United States (US) 13 Signal Food and Drug Administration (FDA) label,1 while the United Kingdom (UK) Summary of Product Characteristics (SmPC) allows for 1000 mg daily for specific infections." ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg" ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 1000 ,
                                                                                  250 ,
                                                                                  750 ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "1000 mg" ,
                                                                                             "250 mg" ,
                                                                                             "750 mg" ;
                        rdfs:label "levofloxacin dosage" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#DoseRange
:DoseRange rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Daily doses ranged from 125 mg to 1000 mg (17 patients)" ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg" ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 1000 ,
                                                                     125 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "1000 mg" ,
                                                                                "125 mg" ;
           rdfs:label "Dose range" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Dose_2_for_Patient_3
:Dose_2_for_Patient_3 rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg" ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 500 ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "500 mg" ;
                      <http://www.w3.org/2006/time#nominalPosition> "days" ;
                      <http://www.w3.org/2006/time#numericDuration> 1 ;
                      rdfs:label "Dose 2 for Patient 3" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Encephalopathy
:Encephalopathy rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "G93.4" ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10014625 ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Encephalopathy" ;
                rdfs:label "Encephalopathy" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Epididymitis
:Epididymitis rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "N45" ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10015000 ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Epididymitis" ;
              rdfs:label "Epididymitis" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Esomeprazole
:Esomeprazole rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A02BC05" ,
                                                                           "A02BD06" ,
                                                                           "M01AE52" ;
              rdfs:label "Esomeprazole" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Ethambutol
:Ethambutol rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "J04AK02" ,
                                                                         "J04AM03" ,
                                                                         "J04AM06" ;
            rdfs:label "Ethambutol" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Fluindione
:Fluindione rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "B01AA12" ;
            rdfs:label "Fluindione" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Fluoroquinolones_and_NMDA_receptors
:Fluoroquinolones_and_NMDA_receptors rdf:type owl:NamedIndividual ,
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect_Mechanism> ;
                                     mp:references :Ref.1 ,
                                                   :Ref.5 ;
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Fluoroquinolones are known to cause central nervous system (CNS) adverse effects such as hallucinations and seizures.1 These effects are likely to be the result of excitation of N-methyl-Daspartate (NMDA) receptors and inhibition of gamma-aminobutyric acid (GABA-A) receptors" ;
                                     rdfs:label "Fluoroquinolones and CNS adverse effects" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Furosemide
:Furosemide rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C03CA01" ,
                                                                         "C03CB01" ,
                                                                         "C03EB01" ,
                                                                         "G01AE10" ;
            rdfs:label "Furosemide" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#GlycerylTrinitrate
:GlycerylTrinitrate rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C01DA02" ;
                    rdfs:label "Glyceryl trinitrate" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Hydrocortisone
:Hydrocortisone rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A01AC03" ,
                                                                             "A07EA02" ,
                                                                             "C05AA01" ,
                                                                             "D07AA02" ,
                                                                             "D07AB02" ,
                                                                             "D07AC16" ,
                                                                             "D07BA04" ,
                                                                             "D07BB04" ,
                                                                             "D07CA01" ,
                                                                             "D07XA01" ,
                                                                             "H02AB09" ,
                                                                             "R01AD60" ,
                                                                             "S01BA02" ,
                                                                             "S01BB01" ,
                                                                             "S01CA03" ,
                                                                             "S01CB03" ,
                                                                             "S02BA01" ,
                                                                             "S02CA03" ,
                                                                             "S03CA04" ;
                rdfs:label "Hydrocortisone" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Hypernatremia
:Hypernatremia rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Potential_Confounder> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "E87.0" ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10020679 ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Hypernatraemia" ;
               rdfs:label "Hypernatremia" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#IC005_for_levofloxacin_and_myoclonus_for_the_elderly
:IC005_for_levofloxacin_and_myoclonus_for_the_elderly rdf:type owl:NamedIndividual ,
                                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component__025_(IC025)> ;
                                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Myoclonus ;
                                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Levofloxacin ;
                                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_information_component> :IC_for_levofloxacin_and_myoclonus_for_the_elderly ;
                                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_min_age> 75 ;
                                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 0.05 ;
                                                      rdfs:label "IC025 for levofloxacin and myoclonus for the elderly" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#IC_for_levofloxacin_and_myoclonus_for_the_elderly
:IC_for_levofloxacin_and_myoclonus_for_the_elderly rdf:type owl:NamedIndividual ,
                                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component_(IC)> ;
                                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Myoclonus ;
                                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Levofloxacin ;
                                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_min_age> 75 ;
                                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 1.16 ;
                                                   rdfs:label "IC for levofloxacin and myoclonus for the elderly" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Impaired_renal_function_and_levofloxacin
:Impaired_renal_function_and_levofloxacin rdf:type owl:NamedIndividual ,
                                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect_Mechanism> ;
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Although the product labels indicate that increasing age alone does not increase the risk of levofloxacin-related CNS adverse effects these are more likely to occur in the elderly as renal function diminishes with age, accelerated by some age-related clinical conditions. This decline may not always be detected if serum creatinine is low due to decreased muscle mass. Thus, accurate measurement of renal function and dose adjustment to avoid accumulation of levofloxacin is essential." ;
                                          rdfs:label "Impaired renal function and levofloxacin" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#InformationForReport1
:InformationForReport1 rdf:type owl:NamedIndividual ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """Recovery on dechallenge. Normal
renal function. Isoniazid-related
peripheral neuropathy.""" ;
                       rdfs:label "Information for Report 1" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#InformationForReport10
:InformationForReport10 rdf:type owl:NamedIndividual ,
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """Recovery on dechallenge.
Preceding haemorrhagic stroke
possible. Ofloxacin serum level
18.4 mcg/mL. EEG slow, no
epileptic elements.""" ;
                        rdfs:label "Information for Report 10" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#InformationForReport11
:InformationForReport11 rdf:type owl:NamedIndividual ,
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """Recovery on dechallenge Cr Cl
30mL/min. Meningeal
haemorrhage on lumbar puncture
but not on scan.
EEG very slow suggesting
encephalopathy of metabolic origin.
INR 10.8, Levofloxacin serum level
9 mcg/mL.""" ;
                        rdfs:label "Information for Report 11" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#InformationForReport2
:InformationForReport2 rdf:type owl:NamedIndividual ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """Recovery on dechallenge and
positive rechallenge""" ;
                       rdfs:label "Information for Report 2" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#InformationForReport3
:InformationForReport3 rdf:type owl:NamedIndividual ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """Recovery on levofloxacin
dechallenge, ceftriaxone continued.
Sensorimotor deficit, Cr Cl
Clearance 34mL/min one month
prior to levofloxacin, normal on
starting.""" ;
                       rdfs:label "Information for Report 3" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#InformationForReport4
:InformationForReport4 rdf:type owl:NamedIndividual ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """Recovery on dechallenge. Treated
with clonazepam and
levetiracetam. Myoclonus
considered epileptic. Cortico-sub
cortical atrophy.""" ;
                       rdfs:label "Information for Report 4" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#InformationForReport5
:InformationForReport5 rdf:type owl:NamedIndividual ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """Recovery of myoclonus on
dechallenge. Dementia. Died of
pneumopathy.""" ;
                       rdfs:label "Information for Report 5" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#InformationForReport6
:InformationForReport6 rdf:type owl:NamedIndividual ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """Recovery myoclonus & aggravated
renal failure on dechallenge,
levofloxacin and concomitants.
Treated with clonazepam. Cardiac
failure likely cause of aggravated
renal failure.""" ;
                       rdfs:label "Information for Report 6" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#InformationForReport7
:InformationForReport7 rdf:type owl:NamedIndividual ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """Recovery on dechallenge.
Parkinsonâ€™s Disease, severe
hypernatremia. Cortical and
subcortical atrophy, sepsis, lactic
acidosis.""" ;
                       rdfs:label "Information for Report 7" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#InformationForReport8
:InformationForReport8 rdf:type owl:NamedIndividual ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """Recovery on dechallenge.
Possible medication error, not
confirmed.""" ;
                       rdfs:label "Information for Report 8" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#InformationForReport9
:InformationForReport9 rdf:type owl:NamedIndividual ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Recovery on dechallenge." ;
                       rdfs:label "Information for Report 9" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#IsosorbideDinitrate
:IsosorbideDinitrate rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C01DA08" ,
                                                                                  "C01DA58" ,
                                                                                  "C05AE02" ;
                     rdfs:label "Isosorbide Dinitrate" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#LacticAcidosis
:LacticAcidosis rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Potential_Confounder> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "E87.2" ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10023676 ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Lactic acidosis" ;
                rdfs:label "Lactic acidosis" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Levofloxacin
:Levofloxacin rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#hasClass> :fluoroquinolones ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_mechanism> :Mechanism_of_levofloxacin ,
                                                                            :Other_possible_mechanism_of_myoclonus ,
                                                                            :Pharmacokinetics_of_levofloxacin ,
                                                                            :Serotonin_syndrome_possible_mechanism ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "J01MA12" ;
              rdfs:label "Levofloxacin" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#LevofloxacinAndCNSReactions
:LevofloxacinAndCNSReactions rdf:type owl:NamedIndividual ,
                                      <http://purl.obolibrary.org/obo/OAE_0001197> ,
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Structured_Product_Labels_information> ,
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Warning_Information> ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_part_of> :Literature_and_Labelling ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CNSStimulation ,
                                                                                                      :Encephalopathy ,
                                                                                                      :PeripheralNeuropathy ,
                                                                                                      :Seizures ,
                                                                                                      :convulsions ,
                                                                                                      :intracranialPressure ,
                                                                                                      :phychosis ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_class> :fluoroquinolones ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Levofloxacin ;
                             mp:references :Ref.1 ,
                                           :Ref.2 ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "The US FDA label for levofloxacin1 lists convulsions and toxic psychoses as the major CNS reactions reported with fluoroquinolones in clinical trials. A number of other psychiatric and nervous system reactions are listed. These have not been confined to the elderly or those with predisposing conditions. Fluoroquinolones may also increase intracranial pressure and cause CNS stimulation. Peripheral neuropathy has been reported rarely and isolated cases of encephalopathy have been observed since marketing. Myoclonus may therefore be an outcome of other levofloxacin adverse reactions such as seizure activity, encephalopathy and peripheral neuropathy. The elderly are noted to be at increased risk of certain fluoroquinolone-related disorders but these do not include CNS adverse effects. There is a warning that, as with other fluoroquinolones, levofloxacin should be used with caution in patients with a known or suspected CNS disorder that may predispose them to seizures or lower the seizure threshold (e.g., severe cerebral arteriosclerosis, epilepsy) or in the presence of other risk factors that may predispose them to seizures or lower the seizure threshold (e.g., certain drug therapy, renal dysfunction). Recommended dose adjustments for renal failure are provided to avoid levofloxacin accumulation. The UK SmPC for levofloxacin contains similar information.2" ;
                             rdfs:label "US FDA label and UK SmPC for Levofloxacin-Fluoroquinolones and CNS reactions" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Levofloxacin_usage
:Levofloxacin_usage rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#concerns_indication_for_use> :acuteBacterialSinusitis ,
                                                                                                :chronicBacterialProstatitis ,
                                                                                                :chronicBronchitis ,
                                                                                                :pneumonia ,
                                                                                                :pyelonephritis ,
                                                                                                :urinaryTractInfections ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Levofloxacin ;
                    rdfs:label "Levofloxacin usage" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Levofloxacin_usage_for_Report1
:Levofloxacin_usage_for_Report1 rdf:type owl:NamedIndividual ,
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :DoseForPatient1 ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Levofloxacin ;
                                rdfs:label "Usage for Report 1" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Levofloxacin_usage_for_Report10
:Levofloxacin_usage_for_Report10 rdf:type owl:NamedIndividual ,
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_related_with_drug_intake> :levofloxacin_intravenous_intake_form ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :DoseForPatient10 ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Levofloxacin ;
                                 rdfs:label "Usage for Report 10" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Levofloxacin_usage_for_Report11
:Levofloxacin_usage_for_Report11 rdf:type owl:NamedIndividual ,
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_related_with_drug_intake> :levofloxacin_intake_form ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :DoseForPatient11 ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Levofloxacin ;
                                 rdfs:label "Usage for Report 11" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Levofloxacin_usage_for_Report2
:Levofloxacin_usage_for_Report2 rdf:type owl:NamedIndividual ,
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :DoseForPatient2 ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Levofloxacin ;
                                rdfs:label "Usage for Report 2" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Levofloxacin_usage_for_Report3
:Levofloxacin_usage_for_Report3 rdf:type owl:NamedIndividual ,
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_related_with_drug_intake> :levofloxacin_intake_form ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :DoseForPatient3 ,
                                                                                                 :Dose_2_for_Patient_3 ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Levofloxacin ;
                                rdfs:label "Usage for Report 3" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Levofloxacin_usage_for_Report4
:Levofloxacin_usage_for_Report4 rdf:type owl:NamedIndividual ,
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_related_with_drug_intake> :levofloxacin_intake_form ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :DoseForPatient4 ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Levofloxacin ;
                                rdfs:label "Usage for Report 4" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Levofloxacin_usage_for_Report5
:Levofloxacin_usage_for_Report5 rdf:type owl:NamedIndividual ,
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_related_with_drug_intake> :levofloxacin_intake_form ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :DoseForPatient5 ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Levofloxacin ;
                                rdfs:label "Usage for Report 5" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Levofloxacin_usage_for_Report6
:Levofloxacin_usage_for_Report6 rdf:type owl:NamedIndividual ,
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_related_with_drug_intake> :levofloxacin_intake_form ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :DoseForPatient6 ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Levofloxacin ;
                                rdfs:label "Usage for Report 6" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Levofloxacin_usage_for_Report7
:Levofloxacin_usage_for_Report7 rdf:type owl:NamedIndividual ,
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_related_with_drug_intake> :levofloxacin_intake_form ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :DoseForPatient7 ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Levofloxacin ;
                                rdfs:label "Usage for Report 7" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Levofloxacin_usage_for_Report8
:Levofloxacin_usage_for_Report8 rdf:type owl:NamedIndividual ,
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_related_with_drug_intake> :levofloxacin_intake_form ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :DoseForPatient8 ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Levofloxacin ;
                                rdfs:label "Usage for Report 8" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Levofloxacin_usage_for_Report9
:Levofloxacin_usage_for_Report9 rdf:type owl:NamedIndividual ,
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_related_with_drug_intake> :levofloxacin_intake_form ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :DoseForPatient9 ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Levofloxacin ;
                                rdfs:label "Usage for Report 9" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Levofloxacin_usage_in_reports
:Levofloxacin_usage_in_reports rdf:type owl:NamedIndividual ,
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :DoseRange ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Levofloxacin ;
                               rdfs:label "Levofloxacin usage in reports" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Literature_and_Labelling
:Literature_and_Labelling rdf:type owl:NamedIndividual ,
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Literature_information> ;
                          mp:references :Ref.1 ,
                                        :Ref.12 ,
                                        :Ref.2 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Myoclonus is not listed as an adverse reaction to levofloxacin in the US FDA label or the UK SmPC.1,2 The US FDA label for levofloxacin1 lists convulsions and toxic psychoses as the major CNS reactions reported with fluoroquinolones in clinical trials. A number of other psychiatric and nervous system reactions are listed. These have not been confined to the elderly or those with predisposing conditions. Fluoroquinolones may also increase intracranial pressure and cause CNS stimulation. Peripheral neuropathy has been reported rarely and isolated cases of encephalopathy have been observed since marketing. Myoclonus may therefore be an outcome of other levofloxacin adverse reactions such as seizure activity, encephalopathy and peripheral neuropathy. The elderly are noted to be at increased risk of certain fluoroquinolone-related disorders but these do not include CNS adverse effects. There is a warning that, as with other fluoroquinolones, levofloxacin should be used with caution in patients with a known or suspected CNS disorder that may predispose them to seizures or lower the seizure threshold (e.g., severe cerebral arteriosclerosis, epilepsy) or in the presence of other risk factors that may predispose them to seizures or lower the seizure threshold (e.g., certain drug therapy, renal dysfunction). Recommended dose adjustments for renal failure are provided to avoid levofloxacin accumulation. The UK SmPC for levofloxacin contains similar information.2 In 2011, a review was published of psychiatric and neurological adverse reactions attributed to fluoroquinolones, identified through published case reports and case series.12 Out of the total of 206 adverse reactions, convulsions were most frequently reported. There were six reports of myoclonus, none attributed to levofloxacin. The authors also noted that fluoroquinolone CSF penetration can increase with meningeal inflammation. Levofloxacin is listed as one of the least likely of the fluoroquinolones to cause CNS adverse effects because of low CSF penetration. Although, at the time of the study, ciprofloxacin and levofloxacin were the most widely marketed fluoroquinolones, only 10 adverse reactions attributed to levofloxacin were identified. These included grand mal convulsions (3) and delirium (2). In keeping with the observations in the VigiBase reports of myoclonus, CNS adverse effects occurred within a few minutes or the first few days of fluoroquinolone treatment and the majority of patients recovered without sequelae when the fluoroquinolone was stopped. Myoclonus occurred with concomitant ofloxacin and pefloxacin in the presence of renal failure in one case report discussed.12" ;
                          rdfs:label "Literature and Labelling" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Mechanism_of_levofloxacin
:Mechanism_of_levofloxacin rdf:type owl:NamedIndividual ,
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Mechanism> ;
                           mp:references :Ref.1 ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class" ;
                           rdfs:label "Mechanism of levofloxacin" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Molsidomine
:Molsidomine rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C01DX12" ;
             rdfs:label "Molsidomine" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Myalgia
:Myalgia rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "M79.1" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10028411 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Myalgia" ;
         rdfs:label "Myalgia" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Myoclonus
:Myoclonus rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "G25.3" ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10028622 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Myoclonus" ;
           rdfs:label "Myoclonus" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Myoclonus_as_ADR
:Myoclonus_as_ADR rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Myoclonus ;
                  mp:references :Ref.6 ,
                                :Ref.8 ,
                                :Ref.9 ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """\"Myoclonus is a neurological sign described as
involuntary and sudden contractions of a muscle or
group of muscles affecting the arms, legs, face,
neck or other parts of the body, resulting in
twitches or jerks. It can result in debilitating
impairment for which specific treatment is
needed.6,7 Myoclonus is associated with a wide
range of clinical conditions and can be of cortical,
subcortical or spinal origin. There is therefore no
specific age range that is typically affected. It can
occur with both focal nervous system damage and
metabolic disorders including renal failure,
electrolyte abnormalities and hypoxia. It can occur
with epilepsy, peripheral motor neuropathy and
encephalopathy, all of which are recognised
adverse effects of fluoroquinolones.6,8 Published
case reports and case series have implicated a
range of medicines in the development of
myoclonus, the most frequently reported being
opiates, antidepressants, antipsychotics and
antibiotics including beta-lactams and
fluoroquinolones.9 \"""" ;
                  rdfs:label "Myoclonus pathophysiology" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Nervous_system_disorders
:Nervous_system_disorders rdf:type owl:NamedIndividual ,
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "G98" ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10029205 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Nervous system disorders" ;
                          rdfs:label "Nervous system disorders" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Omeprazole
:Omeprazole rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A02BC01" ,
                                                                         "A02BD01" ,
                                                                         "A02BD05" ;
            rdfs:label "Omeprazole" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#OnsetWith16Days
:OnsetWith16Days rdf:type owl:NamedIndividual ,
                          <http://www.w3.org/2006/time#DurationDescription> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "The duration of levofloxacin use to onset of myoclonus (16 patients) was 1 to 16 days, mean 5.1 days. " ;
                 rdfs:label "Onset with 16 days" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#OnsetWithin7Days
:OnsetWithin7Days rdf:type owl:NamedIndividual ,
                           <http://www.w3.org/2006/time#DurationDescription> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "For 14 patients, onset was within one week" ;
                  rdfs:label "Onset within 7 days" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Other_possible_mechanism_of_myoclonus
:Other_possible_mechanism_of_myoclonus rdf:type owl:NamedIndividual ,
                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect_Mechanism> ;
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Myoclonus ;
                                       mp:references :Ref.10 ;
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """The authors of this published report suggested potential competition between 
levofloxacin and memantine for renal excretion via organic cation transporters (OCTs), as well as chlorphenamine and dextromethorphan contributing to the symptoms.10""" ;
                                       rdfs:label "Other possible mechanism of myoclonus" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#OverallReportsInVigibase
:OverallReportsInVigibase rdf:type owl:NamedIndividual ,
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Levofloxacin ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_unconfirmed_adverse_effect> :Myoclonus ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 45 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                          rdfs:label "Overall reports in Vigibase" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Patient1
:Patient1 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 78 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
          rdfs:label "Patient 1" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Patient10
:Patient10 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 79 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 10" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Patient11
:Patient11 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 89 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 11" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Patient2
:Patient2 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 80 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
          rdfs:label "Patient 2" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Patient3
:Patient3 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 79 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
          rdfs:label "Patient 3" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Patient4
:Patient4 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 81 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
          rdfs:label "Patient 4" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Patient5
:Patient5 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 78 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
          rdfs:label "Patient 5" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Patient6
:Patient6 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 78 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
          rdfs:label "Patient 6" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Patient7
:Patient7 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 82 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
          rdfs:label "Patient 7" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Patient8
:Patient8 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 86 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
          rdfs:label "Patient 8" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Patient9
:Patient9 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 78 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
          rdfs:label "Patient 9" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#PeripheralNeuropathy
:PeripheralNeuropathy rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Potential_Confounder> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "G90.09" ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10029331 ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Neuropathy peripheral" ;
                      rdfs:label "Peripheral neuropathy" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Pharmacokinetics_of_levofloxacin
:Pharmacokinetics_of_levofloxacin rdf:type owl:NamedIndividual ,
                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Mechanism> ;
                                  mp:references :Ref.1 ,
                                                :Ref.3 ,
                                                :Ref.4 ;
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "The preferred route of administration is oral, showing a rapid and almost complete absorption after 1-2 hours and 99-100% bioavailability. It is excreted primarily as unchanged drug in the urine within 48 hours of administration, by tubular secretion in addition to glomerular filtration. In patients with impaired renal function (creatinine clearance < 50 mL/min), adjustment of the dose regimen, relative to the recommended dose for the indication, is necessary to avoid levofloxacin accumulation.1 Levofloxacin has been shown to penetrate a range of peripheral tissues1 but it is believed that its penetration into cerebrospinal fluid (CSF) is poor. In vitro and in vivo studies have suggested that the brain distribution of several quinolones is restricted by the operation of multiple efflux transporters" ;
                                  rdfs:label "Pharmacokinetics of levofloxacin" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Potassium
:Potassium rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A12BA" ;
           rdfs:label "Potassium" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Prostatititis
:Prostatititis rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "N41" ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10036978 ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Prostatitis	" ;
               rdfs:label "Prostatitis" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Psychiatric_disorders
:Psychiatric_disorders rdf:type owl:NamedIndividual ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "F99" ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10037175 ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Psychiatric disorders" ;
                       rdfs:label "Psychiatric disorders" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Ref.1
:Ref.1 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> " 1. US Food and Drug Administration: Product label for levofloxacin (LEVAQUINÂ®). Revised February 2017. Available from: https://www.accessdata.fda. gov/drugsatfda_docs/label/2017/020634s068, 02063 5s074,021721s035lbl.pdf. Accessed: February 2018. " ;
       rdfs:label "Ref. 1" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Ref.10
:Ref.10 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "10. Pei LJ, Tianzhi IL, Lim WS. MemantineInduced Myoclonus Precipitated by Renal Impairment and Drug Interactions. J Am. Geriatr Soc 2015; 63: 2644-2655. " ;
        rdfs:label "Ref. 10" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Ref.11
:Ref.11 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "11. Hitchings A. Drugs that lower the seizure threshold. http://openaccess.sgul.ac.uk/108264/1/ Hitchings%20-%20Drugs%20that%20lower% 20 the%20seizure%20threshold%20-%20Author %20 final%20version.pdf. Accessed February 2018. " ;
        rdfs:label "Ref. 11" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Ref.12
:Ref.12 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "12. Tome AM, Filipe A. Quinolones. Review of psychiatric and neurological adverse reactions. Drug Saf 2011; 34: 465-488. " ;
        rdfs:label "Ref. 12" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Ref.13
:Ref.13 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "13. Czock, D., & Rasche, F. M. (2005). Dose adjustment of ciprofloxacin in renal failure: Reduce the dose or prolong the administration interval? Eur J Med Res, 10, 145-148. " ;
        rdfs:label "Ref. 13" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Ref.14
:Ref.14 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "14. Leroy, B., Uhart, M., Maire, P., & Bourguignon, L. (2012). Evaluation of fluoroquinolone reduced dosage regimens in elderly patients by using pharmacokinetic modelling and Monte Carlo simulations. J Antimicrob Chemother, 67(9), 2207-2212. " ;
        rdfs:label "Ref. 14" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Ref.2
:Ref.2 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "2. Electronic Medicines Compendium: Summary of Product Characteristics for Levofloxacin 500 mg film-coated tablets. Last updated on 16 Nov 2017. Available from: https://www.medicines.org.uk/emc/ product/8635. Accessed: February 2018. " ;
       rdfs:label "Ref. 2" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Ref.3
:Ref.3 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "3. Drug Bank: Levofloxacin. Available from https://www.drugbank.ca/drugs/DB01137 Accessed: October 2017. " ;
       rdfs:label "Ref. 3" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Ref.4
:Ref.4 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "4. Tamai I, Yamashita J, Kido Y et al. Limited Distribution of New Quinolone Antibacterial Agents into Brain Caused by Multiple Efflux Transporters at the Blood-Brain Barrier. J. Pharmacol. Exp. Ther. 2000; 295: 146-152. " ;
       rdfs:label "Ref. 4" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Ref.5
:Ref.5 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "5. Kunder SK, Avinash A, Nayak V et al. A Rare Instance of Levofloxacin Induced Myoclonus. J Clin Diagn Res 2017;11:FD01-FD02. " ;
       rdfs:label "Ref. 5" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Ref.6
:Ref.6 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "6. Kojovic M, Cordivari C, Bhatia K. Myoclonic disorders: a practical approach for diagnosis and treatment. Ther Adv Neurol Disord 2011; 4: 47-62. " ;
       rdfs:label "Ref. 6" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Ref.7
:Ref.7 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "7. US National Institute of Neurological Disorders and Stroke: Myoclonus Fact Sheet, 2017. https:// www.ninds.nih.gov/Disorders/PatientCaregiver- Education/Fact-Sheets/MyoclonusFact-Sheet Accessed: October 2017. " ;
       rdfs:label "Ref. 7" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Ref.8
:Ref.8 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "8. Warren Olanow C, Schapira AHV, Obeso JA. Harrisonâ€™s Principles of Internal Medicine. 19th edition. USA: McGraw-Hill Education; 2015. Chapter 449, Parkinsonâ€™s disease and other movement disorders. " ;
       rdfs:label "Ref. 8" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Ref.9
:Ref.9 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "9. Janssen S, Bloem BR, van de Warrenburg, BP. The clinical heterogeneity of drug-induced myoclonus: an illustrated review. J Neurol 2017; 264: 1599-1566. " ;
       rdfs:label "Ref. 9" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#RenalFailureAggrevated
:RenalFailureAggrevated rdf:type owl:NamedIndividual ,
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "N19" ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10038435 ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Renal failure" ;
                        rdfs:label "Renal failure aggrevated" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Report1
:Report1 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#concerns_indication_for_use> :pulmonaryTuberculosis ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_free_text_reporting_element> :InformationForReport1 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_potential_confounding_factor> :PeripheralNeuropathy ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Chorea ,
                                                                                  :Myoclonus ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Ethambutol ,
                                                                                    :rifampicin ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient1 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Levofloxacin ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_reported_drug_usage> :Levofloxacin_usage_for_Report1 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :TimeToOnsetForPatient1 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_outcome> "positive - condition not applied" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery after drug withdrawal" ;
         rdfs:label "Report 1" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Report10
:Report10 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#concerns_indication_for_use> :Bronchitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_free_text_reporting_element> :InformationForReport10 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Encephalopathy ,
                                                                                   :Myoclonus ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Ticarcillin ,
                                                                                     :clavulonic_acid ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient10 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Levofloxacin ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_reported_drug_usage> :Levofloxacin_usage_for_Report10 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :TimeToOnsetForPatient10 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_outcome> "positive - condition not applied" ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery after drug withdrawal" ;
          rdfs:label "Report 10" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Report11
:Report11 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_free_text_reporting_element> :InformationForReport11 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Encephalopathy ,
                                                                                   :Myoclonus ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Amiodarone ,
                                                                                     :Digoxin ,
                                                                                     :Fluindione ,
                                                                                     :Furosemide ,
                                                                                     :IsosorbideDinitrate ,
                                                                                     :Molsidomine ,
                                                                                     :ambroxol ,
                                                                                     :lansoprazole ,
                                                                                     :metoclopramide ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient11 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Levofloxacin ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_reported_drug_usage> :Levofloxacin_usage_for_Report11 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :TimeToOnsetForPatient11 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_outcome> "positive - condition not applied" ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery after drug withdrawal" ;
          rdfs:label "Report 11" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Report2
:Report2 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#concerns_indication_for_use> :pneumonia ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_free_text_reporting_element> :InformationForReport2 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Myoclonus ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient2 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Levofloxacin ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_reported_drug_usage> :Levofloxacin_usage_for_Report2 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :TimeToOnsetForPatient2 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_outcome> "positive - condition not applied" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery after drug withdrawal" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_rechallenge_outcome> "positive rechallenge - condition appeared again" ;
         rdfs:label "Report 2" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Report3
:Report3 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#concerns_indication_for_use> :Bronchitis ,
                                                                                     :Epididymitis ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_free_text_reporting_element> :InformationForReport3 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Myalgia ,
                                                                                  :Myoclonus ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Bisoprolol ,
                                                                                    :Ceftriaxone ,
                                                                                    :Omeprazole ,
                                                                                    :Potassium ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient3 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Levofloxacin ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_reported_drug_usage> :Levofloxacin_usage_for_Report3 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :TimeToOnsetForPatient3 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_outcome> "positive - condition not applied" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery after drug withdrawal" ;
         rdfs:label "Report 3" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Report4
:Report4 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#concerns_indication_for_use> :Bronchitis ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_free_text_reporting_element> :InformationForReport4 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_potential_confounding_factor> :CorticalAtrophy ,
                                                                                          :SubcorticalAtrophy ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Myoclonus ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :AcetylsalicylicAcid ,
                                                                                    :Alfuzosin ,
                                                                                    :Atorvastatin ,
                                                                                    :Bisoprolol ,
                                                                                    :Clopidogrel ,
                                                                                    :Esomeprazole ,
                                                                                    :Furosemide ,
                                                                                    :GlycerylTrinitrate ,
                                                                                    :amlodipine ,
                                                                                    :paracetamol ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient4 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Levofloxacin ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_reported_drug_usage> :Levofloxacin_usage_for_Report4 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :TimeToOnsetForPatient4 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_outcome> "positive - condition not applied" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery after drug withdrawal" ;
         rdfs:label "Report 4" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Report5
:Report5 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#concerns_indication_for_use> :Prostatititis ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_free_text_reporting_element> :InformationForReport5 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_potential_confounding_factor> :Dementia ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Coma ,
                                                                                  :Dementia ,
                                                                                  :Myoclonus ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Bicalutamide ,
                                                                                    :Donepezil ,
                                                                                    :memantine ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient5 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Levofloxacin ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_reported_drug_usage> :Levofloxacin_usage_for_Report5 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :TimeToOnsetForPatient5 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_outcome> "positive - condition not applied" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery after drug withdrawal" ;
         rdfs:label "Report 5" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Report6
:Report6 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#concerns_indication_for_use> :urinaryTractInfections ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_free_text_reporting_element> :InformationForReport6 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Myoclonus ,
                                                                                  :RenalFailureAggrevated ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Furosemide ,
                                                                                    :Hydrocortisone ,
                                                                                    :Omeprazole ,
                                                                                    :Spironolactone ,
                                                                                    :Zolpidem ,
                                                                                    :paracetamol ,
                                                                                    <http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Amoxicillin/clavulanicAcid> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient6 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Levofloxacin ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_reported_drug_usage> :Levofloxacin_usage_for_Report6 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :TimeToOnsetForPatient6 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_outcome> "positive - condition not applied" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery after drug withdrawal" ;
         rdfs:label "Report 6" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Report7
:Report7 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#concerns_indication_for_use> :Bronchitis ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_free_text_reporting_element> :InformationForReport7 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_potential_confounding_factor> :CorticalAtrophy ,
                                                                                          :Hypernatremia ,
                                                                                          :LacticAcidosis ,
                                                                                          :Sepsis ,
                                                                                          :SubcorticalAtrophy ,
                                                                                          <http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Parkinson's_disease> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Encephalopathy ,
                                                                                  :Myoclonus ,
                                                                                  :cheyne ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :AcetylsalicylicAcid ,
                                                                                    :hydrochlorothiazide ,
                                                                                    :nadolol ,
                                                                                    :urapidil ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient7 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Levofloxacin ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_reported_drug_usage> :Levofloxacin_usage_for_Report7 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :TimeToOnsetForPatient7 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_outcome> "positive - condition not applied" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery after drug withdrawal" ;
         rdfs:label "Report 7" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Report8
:Report8 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#concerns_indication_for_use> :Acute_bronchitis ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_free_text_reporting_element> :InformationForReport8 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Myoclonus ,
                                                                                  :VisualHallucination ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient8 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Levofloxacin ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_reported_drug_usage> :Levofloxacin_usage_for_Report8 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :TimeToOnsetForPatient8 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_outcome> "positive - condition not applied" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery after drug withdrawal" ;
         rdfs:label "Report 8" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Report9
:Report9 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#concerns_indication_for_use> :RespiratoryInfection ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_free_text_reporting_element> :InformationForReport9 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Myoclonus ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient9 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Levofloxacin ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_reported_drug_usage> :Levofloxacin_usage_for_Report9 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :TimeToOnsetForPatient9 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_outcome> "positive - condition not applied" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery after drug withdrawal" ;
         rdfs:label "Report 9" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#ReportsDechallengedHavingRecoveryAsOutcome
:ReportsDechallengedHavingRecoveryAsOutcome rdf:type owl:NamedIndividual ,
                                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 11 ;
                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_outcome> "positive - condition not applied" ;
                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery after drug withdrawal" ;
                                            rdfs:label "Reports dechallenged having recovery as outcome" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#ReportsInVigibaseForCasesLessThan75
:ReportsInVigibaseForCasesLessThan75 rdf:type owl:NamedIndividual ,
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :ReportsInVigibaseInWhichAgeIsMentioned ;
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 18 ;
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_max_age> 75 ;
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_median_age> 58 ;
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                     rdfs:label "Reports in Vigibase for cases less than 75" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#ReportsInVigibaseForCasesOver75
:ReportsInVigibaseForCasesOver75 rdf:type owl:NamedIndividual ,
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :ReportsInVigibaseInWhichAgeIsMentioned ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 20 ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count_of_men> 9 ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count_of_women> 11 ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_max_age> 100 ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_median_age> "81.0"^^xsd:float ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_min_age> 78 ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                 rdfs:label "Reports in Vigibase for cases over 75" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#ReportsInVigibaseInWhichAgeIsMentioned
:ReportsInVigibaseInWhichAgeIsMentioned rdf:type owl:NamedIndividual ,
                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 38 ;
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count_of_men> 20 ;
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count_of_women> 18 ;
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_max_age> 100 ;
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_median_age> 78 ;
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_min_age> 15 ;
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                        rdfs:label "Reports in Vigibase in which age is mentioned" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#ReportsInWhichLevofloxacinWasTheOnlySuspectDrug
:ReportsInWhichLevofloxacinWasTheOnlySuspectDrug rdf:type owl:NamedIndividual ,
                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Levofloxacin ;
                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 14 ;
                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                 rdfs:label "Reports in which levofloxacin was the only suspect drug" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#ReportsWithAnOnsetWithin16Days
:ReportsWithAnOnsetWithin16Days rdf:type owl:NamedIndividual ,
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :OnsetWith16Days ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 16 ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                rdfs:label "Reports with an onset within 16 days" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#ReportsWithIntravenousAdministration
:ReportsWithIntravenousAdministration rdf:type owl:NamedIndividual ,
                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_related_with_drug_intake> :levofloxacin_intravenous_intake_form ;
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 3 ;
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                      rdfs:label "Reports with intravenous administration" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#ReportsWithLessThanAWeekOfOnset
:ReportsWithLessThanAWeekOfOnset rdf:type owl:NamedIndividual ,
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :OnsetWithin7Days ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 14 ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                 rdfs:label "Reports with less than a week of onset" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#ReportsWithOralAdministration
:ReportsWithOralAdministration rdf:type owl:NamedIndividual ,
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_related_with_drug_intake> :levofloxacin_intake_form ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 14 ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                               rdfs:label "Reports with oral administration" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#ReportsWithRenalImpairment
:ReportsWithRenalImpairment rdf:type owl:NamedIndividual ,
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :renal_failure ;
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 5 ;
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                            rdfs:label "Reports with renal impairment " .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Reports_in_VigiBase
:Reports_in_VigiBase rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element> ;
                     mp:references :Ref.1 ,
                                   :Ref.10 ,
                                   :Ref.11 ,
                                   :Ref.9 ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "More than five thousand reports for levofloxacin under the MedDRA High Level Term (HLT) â€œNeurological Signs and Symptomsâ€ were identified. These included 45 reports with the MedDRA Preferred Term (PT) myoclonus. More than half (23) were for elderly adults aged 75 years and over, compared with an expected number of 9.5. There were 18 reports for patients aged less than 75 years and in four reports, the age was not stated. All reports entered in VigiBase up to 28 August 2017 for patients aged 75 years and over, in which levofloxacin was a suspect medicine and myoclonus an adverse reaction term, were included in the present analysis. The reports for patients aged 75 years and older originated from nine countries which were predominantly European. Of the 23 reports, three were excluded. One because the original publication that generated the report did not mention myoclonus, and two because they were duplicates. The 20 remaining reports included nine men and 11 women with an age range of 78 to 100 years, median 81 years. In comparison, for all reports where age was stated (38) the age range was 15 to 100 years, median 78 years. Twenty patients were men and 18 were women. Levofloxacin Use Daily doses ranged from 125 mg to 1000 mg (17 patients). The route of administration was oral for 14 patients and intravenous for three. The duration of levofloxacin use to onset of myoclonus (16 patients) was 1 to 16 days, mean 5.1 days. For 14 patients, onset was within one week. Levofloxacin was the only suspect medicine related to myoclonus in 14 reports. The symptoms resolved in 11 patients after withdrawal of levofloxacin. These reports are summarised in Table 1. In three of these 11 reports levofloxacin was listed as the only medicine the patient was taking (2, 8, 9) with recurrence on rechallenge in one (2). In report 6, other non-suspect medicines were also discontinued. Key Case Reports Key case reports include case report 1 (see table 1), which was published5 and describes a 78-year-old patient with alcoholism who was treated for pulmonary tuberculosis with isoniazid, ethambutol and rifampicin. After one month he developed peripheral neuropathy attributed to isoniazid. This medicine was discontinued, rifampicin and ethambutol continued and levofloxacin added. After four days he developed myoclonus and other abnormal movements. Levofloxacin was discontinued. He was treated with diazepam and pyridoxine and recovered. He had no further episodes over the subsequent month, and had normal renal function. Case report 2 was for an 80-year-old male patient who was treated with levofloxacin for pneumonia and developed myoclonus after nine days. He recovered on stopping levofloxacin and experienced recurrence on rechallenge. In case report 3, a 79-year-old patient with pneumopathy and epididymitis was treated with levofloxacin and ceftriaxone for 24 hours after which he developed myoclonus and leg cramps. He was found to have sensorimotor deficiency on examination. Levofloxacin was stopped and ceftriaxone continued. He recovered from myoclonus and muscle pain over five days. Interacting medicines Drug interactions with levofloxacin were suspected in three reports. In one case, inhibition of clomipramine metabolism by levofloxacin was proposed with resulting serotonin syndrome. In another case, the patient, who had impaired renal function, developed myoclonic jerks after taking memantine for Parkinsonâ€™s Disease. After two months the patient commenced levofloxacin, the myoclonic jerks worsened and he became confused. The authors of this published report suggested potential competition between levofloxacin and memantine for renal excretion via organic cation transporters (OCTs), as well as chlorphenamine and dextromethorphan contributing to the symptoms.10 In the third case, the proposed mechanism for an interaction between imipenem and levofloxacin is not recorded but may relate to both fluoroquinolones and beta-lactams predisposing to myoclonus and seizures. Co-suspect and concomitant medicines Co-suspect medicines were usually those also reported to cause myoclonus, e.g., mianserin, codeine and ceftriaxone in three reports. However, myoclonus-inducing medicines were also frequently listed as concomitants. Those reported most often were opioid derivatives in four reports and ceftriaxone in three. The complexity of some reports is illustrated by one case describing a patient who developed myoclonus and abnormal movements followed four days later by status epilepticus while taking 11 medicines including levofloxacin, mianserin, codeine and ceftriaxone, all of which may cause myoclonus9 and predispose to seizures.11 Co-reported adverse reactions and co-morbidities Co-reported adverse reaction terms indicated that some patients had seizures as well as myoclonus. Seizures are rare adverse reactions to levofloxacin1 and it is possible that some patients were having seizure-related myoclonus without fully developed seizures. Three other patients were described as having encephalopathy (case reports 13, 19, and 20) which levofloxacin may have caused or exacerbated. Other patients had conditions that may have predisposed to levofloxacin-related myoclonus or were an alternative explanation for myoclonus. Two had a background of peripheral or polyneuropathy. Others had cerebral disease, including haemorrhage in two patients, and cortical or subcortical atrophy in three. Metabolic disorders and sepsis may also have impacted on the central nervous system in four patients. Moreover, one patient was under gabapentin treatment which suggests the presence of epilepsy or peripheral neuropathic pain. No predisposing or potentially confounding conditions or co-prescriptions were recorded for reports numbered 2, 8 and 9 in Table 1, and these patients improved on levofloxacin dechallenge. The co-reported adverse reactions and medicines, as well as patient co-morbidities, offer alternative explanations for myoclonus in some cases. However, it is also possible that they predisposed to levofloxacin-related myoclonus given the temporal relationships observed in several case reports with starting and stopping this medicine. Renal function Five patients had renal impairment, defined as a creatinine clearance no greater than 50mL/min or specific mention of reduced renal function. Two other reports described renal function as normal at the time of prescription. In the remaining 13 reports renal function was not mentioned, although the dose interval of 48 hours for one of these patients suggested adjustment for renal impairment. It is therefore possible that at least 15 elderly patients with myoclonus did not require levofloxacin dose reduction or that renal function was not measured. Of the five patients with renal impairment, dose adjustments for levofloxacin, as recommended in the US FDA label,1 appear to have been made for one who was prescribed 125 mg daily. Three were taking 500 or 1000 mg daily, and dose was not recorded for the fifth patient. Co-reported adverse reactions and co-morbidities Levofloxacin is the optical S-(-) active isomer of ofloxacin. In two patients with renal impairment ofloxacin levels were 7.4 and 18.4 mcg/mL (therapeutic range 0.5 â€“ 1.5). One had severe renal failure but the levofloxacin dose had been reduced appropriately. Serum ceftriaxone levels were also above therapeutic. This patient recovered when both medicines were stopped. A third patient had a serum levofloxacin level of 9 mcg/mL but a therapeutic range was not reported. Comparison with levofloxacin/myoclonus reports for patients < 75 years An overview of the reports for the 18 patients aged 15 to 74 years, median 58 years, supported a causal role for levofloxacin in this age group. In contrast to the older patients, only two had a potentially predisposing cerebral or metabolic disorder and only one had renal impairment. A similarity with the older group was the level of co-prescription with medicines that might cause myoclonus and lower the seizure threshold (8/20 and 6/18). There was one non-steroidal anti-inflammatory drug (NSAID)/levofloxacin interaction in the younger group." ;
                     rdfs:label "Reports in VigiBase" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#RespiratoryInfection
:RespiratoryInfection rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "J98.8" ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10062352 ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Respiratory tract infection" ;
                      rdfs:label "Respiratory infection" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Review_for_fluoroquinolones_and_psychiatric_and_neurological
:Review_for_fluoroquinolones_and_psychiatric_and_neurological rdf:type owl:NamedIndividual ,
                                                                       <http://purl.obolibrary.org/obo/OAE_0001197> ;
                                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_part_of> :Literature_and_Labelling ;
                                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Myoclonus ,
                                                                                                                                       :Nervous_system_disorders ,
                                                                                                                                       :Psychiatric_disorders ,
                                                                                                                                       :convulsions ,
                                                                                                                                       :delirium ;
                                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_class> :fluoroquinolones ;
                                                              mp:references :Ref.12 ;
                                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "In 2011, a review was published of psychiatric and neurological adverse reactions attributed to fluoroquinolones, identified through published case reports and case series.12 Out of the total of 206 adverse reactions, convulsions were most frequently reported. There were six reports of myoclonus, none attributed to levofloxacin. The authors also noted that fluoroquinolone CSF penetration can increase with meningeal inflammation. Levofloxacin is listed as one of the least likely of the fluoroquinolones to cause CNS adverse effects because of low CSF penetration. Although, at the time of the study, ciprofloxacin and levofloxacin were the most widely marketed fluoroquinolones, only 10 adverse reactions attributed to levofloxacin were identified. These included grand mal convulsions (3) and delirium (2). In keeping with the observations in the VigiBase reports of myoclonus, CNS adverse effects occurred within a few minutes or the first few days of fluoroquinolone treatment and the majority of patients recovered without sequelae when the fluoroquinolone was stopped. Myoclonus occurred with concomitant ofloxacin and pefloxacin in the presence of renal failure in one case report discussed.12" ;
                                                              rdfs:label "Review for fluoroquinolones and psychiatric and neurological" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Savage_Ruth
:Savage_Ruth rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Author> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_affiliation> "New Zealand" ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_first_name> "Ruth" ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_last_name> "Savage" ;
             rdfs:label "Dr. Savage Ruth" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Seizures
:Seizures rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R56.8" ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10039906 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "	Seizure" ;
          rdfs:label "Seizures" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Seizures_and_levofloxacin
:Seizures_and_levofloxacin rdf:type owl:NamedIndividual ,
                                    <http://purl.obolibrary.org/obo/OAE_0001197> ,
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Warning_Information> ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Seizures ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Levofloxacin ;
                           mp:references :Ref.1 ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Seizures are rare adverse reactions to levofloxacin1 and it is possible that some patients were having seizure-related myoclonus without fully developed seizures." ;
                           rdfs:label "Seizures and levofloxacin" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Sepsis
:Sepsis rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Potential_Confounder> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "A41" ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10040047 ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Sepsis" ;
        rdfs:label "Sepsis" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Serotonin_syndrome_possible_mechanism
:Serotonin_syndrome_possible_mechanism rdf:type owl:NamedIndividual ,
                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect_Mechanism> ;
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :serotonin_syndrome ;
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "In one case, inhibition of clomipramine metabolism by levofloxacin was proposed with resulting serotonin syndrome." ;
                                       rdfs:label "Serotonin syndrome possible mechanism" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Spironolactone
:Spironolactone rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C03DA01" ;
                rdfs:label "Spironolactone" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#SubcorticalAtrophy
:SubcorticalAtrophy rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Potential_Confounder> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "G31.9" ;
                    rdfs:label "Subcortical atrophy" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Ticarcillin
:Ticarcillin rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "J01CA13" ,
                                                                          "J01CR03" ,
                                                                          "J01CR50" ;
             rdfs:label "Ticarcillin" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#TimeToOnsetForPatient1
:TimeToOnsetForPatient1 rdf:type owl:NamedIndividual ,
                                 <http://www.w3.org/2006/time#DurationDescription> ;
                        <http://www.w3.org/2006/time#nominalPosition> "days" ;
                        <http://www.w3.org/2006/time#numericPosition> 4 ;
                        rdfs:label "Time to onset for Patient 1" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#TimeToOnsetForPatient10
:TimeToOnsetForPatient10 rdf:type owl:NamedIndividual ,
                                  <http://www.w3.org/2006/time#DurationDescription> ;
                         <http://www.w3.org/2006/time#nominalPosition> "days" ;
                         <http://www.w3.org/2006/time#numericPosition> 4 ;
                         rdfs:label "Time to onset for Patient 10" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#TimeToOnsetForPatient11
:TimeToOnsetForPatient11 rdf:type owl:NamedIndividual ,
                                  <http://www.w3.org/2006/time#DurationDescription> ;
                         <http://www.w3.org/2006/time#nominalPosition> "days" ;
                         <http://www.w3.org/2006/time#numericPosition> 16 ;
                         rdfs:label "Time to onset for Patient 11" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#TimeToOnsetForPatient2
:TimeToOnsetForPatient2 rdf:type owl:NamedIndividual ,
                                 <http://www.w3.org/2006/time#DurationDescription> ;
                        <http://www.w3.org/2006/time#nominalPosition> "days" ;
                        <http://www.w3.org/2006/time#numericPosition> 9 ;
                        rdfs:label "Time to onset for Patient 2" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#TimeToOnsetForPatient3
:TimeToOnsetForPatient3 rdf:type owl:NamedIndividual ,
                                 <http://www.w3.org/2006/time#DurationDescription> ;
                        <http://www.w3.org/2006/time#nominalPosition> "days" ;
                        <http://www.w3.org/2006/time#numericPosition> 1 ;
                        rdfs:label "Time to onset for Patient 3" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#TimeToOnsetForPatient4
:TimeToOnsetForPatient4 rdf:type owl:NamedIndividual ,
                                 <http://www.w3.org/2006/time#DurationDescription> ;
                        <http://www.w3.org/2006/time#nominalPosition> "days" ;
                        <http://www.w3.org/2006/time#numericPosition> 5 ;
                        rdfs:label "Time to onset for Patient 4" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#TimeToOnsetForPatient5
:TimeToOnsetForPatient5 rdf:type owl:NamedIndividual ,
                                 <http://www.w3.org/2006/time#DurationDescription> ;
                        <http://www.w3.org/2006/time#nominalPosition> "days" ;
                        <http://www.w3.org/2006/time#numericPosition> 3 ;
                        rdfs:label "Time to onset for Patient 5" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#TimeToOnsetForPatient6
:TimeToOnsetForPatient6 rdf:type owl:NamedIndividual ,
                                 <http://www.w3.org/2006/time#DurationDescription> ;
                        <http://www.w3.org/2006/time#nominalPosition> "days" ;
                        <http://www.w3.org/2006/time#numericPosition> 7 ;
                        rdfs:label "Time to onset for Patient 6" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#TimeToOnsetForPatient7
:TimeToOnsetForPatient7 rdf:type owl:NamedIndividual ,
                                 <http://www.w3.org/2006/time#DurationDescription> ;
                        <http://www.w3.org/2006/time#nominalPosition> "days" ;
                        <http://www.w3.org/2006/time#numericPosition> 6 ;
                        rdfs:label "Time to onset for Patient 7" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#TimeToOnsetForPatient8
:TimeToOnsetForPatient8 rdf:type owl:NamedIndividual ,
                                 <http://www.w3.org/2006/time#DurationDescription> ;
                        <http://www.w3.org/2006/time#nominalPosition> "days" ;
                        <http://www.w3.org/2006/time#numericPosition> 7 ;
                        rdfs:label "Time to onset for Patient 8" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#TimeToOnsetForPatient9
:TimeToOnsetForPatient9 rdf:type owl:NamedIndividual ,
                                 <http://www.w3.org/2006/time#DurationDescription> ;
                        <http://www.w3.org/2006/time#nominalPosition> "days" ;
                        <http://www.w3.org/2006/time#numericPosition> 4 ;
                        rdfs:label "Time to onset for Patient 9" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#US_FDA_Black_Box_Warning_for_fluoroquinolones
:US_FDA_Black_Box_Warning_for_fluoroquinolones rdf:type owl:NamedIndividual ,
                                                        <http://purl.obolibrary.org/obo/OAE_0001197> ,
                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Structured_Product_Labels_information> ,
                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Warning_Information> ;
                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_class> :fluoroquinolones ;
                                               mp:references :Ref.1 ;
                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "A recent US FDA Black Box Warning for fluoroquinolones advises restriction of the use of these antibiotics in infections for which a choice of antibiotics is available, because of serious reactions including CNS effects" ;
                                               rdfs:label "US FDA Black Box Warning for fluoroquinolones" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Upsalla_Monitoring_Centre
:Upsalla_Monitoring_Centre rdf:type owl:NamedIndividual ,
                                    <http://www.w3.org/ns/prov#Organization> ;
                           rdfs:label "Upsalla Monitoring Centre" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#VisualHallucination
:VisualHallucination rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R44.1" ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10019075 ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Hallucination, visual" ;
                     rdfs:label "Visual hallucination" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Zappacosta_Sofia
:Zappacosta_Sofia rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Author> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_affiliation> "Uppsala Monitoring Centre" ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_first_name> "Sofia" ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_last_name> "Zappacosta" ;
                  rdfs:label "Zappacosta Sofia" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Zolpidem
:Zolpidem rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N05CF02" ;
          rdfs:label "Zolpidem" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#acuteBacterialSinusitis
:acuteBacterialSinusitis rdf:type owl:NamedIndividual ,
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "J01" ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10060841 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Sinusitis bacterial" ;
                         rdfs:label "acute bacterial sinusitis" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#ambroxol
:ambroxol rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "R05CB06" ;
          rdfs:label "ambroxol" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#amlodipine
:amlodipine rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C08CA01" ;
            rdfs:label "amlodipine" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#cheyne
:cheyne rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R06.3" ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10008501 ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Cheyne-Stokes respiration" ;
        rdfs:label "Cheyne-Stokes respiration" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#chlorphenamine
:chlorphenamine rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_mechanism> :Other_possible_mechanism_of_myoclonus ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "R06AB04" ;
                rdfs:label "chlorphenamine" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#chronicBacterialProstatitis
:chronicBacterialProstatitis rdf:type owl:NamedIndividual ,
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "N41.1" ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10069918 ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Bacterial prostatitis" ;
                             rdfs:label "chronic bacterial prostatitis" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#chronicBronchitis
:chronicBronchitis rdf:type owl:NamedIndividual ,
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "J42" ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10006458 ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Bronchitis chronic" ;
                   rdfs:label "chronic bronchitis" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#clavulonic_acid
:clavulonic_acid rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "J01CRâ€Ž" ;
                 rdfs:label "clavulanic acid" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#clomipramine
:clomipramine rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_mechanism> :serotonin_syndrome ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N06AA04" ;
              rdfs:label "clomipramine" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#conclusion
:conclusion rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Conclusion> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Of the 20 VigiBase reports of levofloxacin and myoclonus in the elderly, 11 described a temporal relationship with levofloxacin use that supported causality. In three of these reports there were no medicines or co-morbidities that may have contributed or been alternative explanations. Renal impairment, and CNS conditions that may predispose to myoclonus were more prevalent in the reports for patients over 75 years. In contrast co-prescription of medicines that may cause myoclonus and lower the seizure threshold was prominent in all age groups and the reports are a reminder to identify avoidable combinations." .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#convulsions
:convulsions rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R56" ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10010904 ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> """Convulsion
""" ;
             rdfs:label "convulsions" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#delirium
:delirium rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "F05" ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10012218 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> """Delirium

""" ;
          rdfs:label "delirium" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#dextromethorphan
:dextromethorphan rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_mechanism> :Other_possible_mechanism_of_myoclonus ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "R05DA09" ;
                  rdfs:label "dextromethorphan" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#fluoroquinolones
:fluoroquinolones rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#DrugClass> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_mechanism> :Fluoroquinolones_and_NMDA_receptors ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "J01MA " ;
                  rdfs:label "fluoroquinolones" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#gabapentin
:gabapentin rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N03AX12" ;
            rdfs:label "gabapentin" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#hydrochlorothiazide
:hydrochlorothiazide rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C03AA03" ,
                                                                                  "C03AB03" ,
                                                                                  "C03AX01" ,
                                                                                  "C03EA01" ,
                                                                                  "C09DX01" ,
                                                                                  "C09DX03" ,
                                                                                  "C09XA52" ,
                                                                                  "C09XA54" ,
                                                                                  "G01AE10" ;
                     rdfs:label "hydrochlorothiazide" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#intracranialPressure
:intracranialPressure rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "G93.2" ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10022773 ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> """Intracranial pressure increased
""" ;
                      rdfs:label "intracranial pressure" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#introduction
:introduction rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Introduction> ;
              mp:references :Ref.1 ,
                            :Ref.2 ,
                            :Ref.3 ,
                            :Ref.4 ,
                            :Ref.5 ,
                            :Ref.6 ,
                            :Ref.7 ,
                            :Ref.8 ,
                            :Ref.9 ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "A signal detection screening in VigiBase, the WHO global database of individual case safety reports (ICSRs) focusing on subgroups at risk identified disproportionate reporting of a combination of levofloxacin and myoclonus in the elderly population 75 years and older. As of 25 February 2018, the IC value for the elderly age group was 1.16 (IC025: 0.05). However, the reporting was not disproportionate for all age groups combined. Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class. It is indicated in adults for the treatment of diverse infections such as acute bacterial sinusitis, acute exacerbations of chronic bronchitis, community-acquired pneumonia, chronic bacterial prostatitis, pyelonephritis and complicated urinary tract infections.1 Recommended daily doses range from 250 mg for uncomplicated urinary tract infections to 750 mg for more serious diverse bacterial infections according to the United States (US) â€¢ 13 Signal Food and Drug Administration (FDA) label,1 while the United Kingdom (UK) Summary of Product Characteristics (SmPC) allows for 1000 mg daily for specific infections.2 The preferred route of administration is oral, showing a rapid and almost complete absorption after 1-2 hours and 99-100% bioavailability. It is excreted primarily as unchanged drug in the urine within 48 hours of administration, by tubular secretion in addition to glomerular filtration. In patients with impaired renal function (creatinine clearance < 50 mL/min), adjustment of the dose regimen, relative to the recommended dose for the indication, is necessary to avoid levofloxacin accumulation.1 Levofloxacin has been shown to penetrate a range of peripheral tissues1 but it is believed that its penetration into cerebrospinal fluid (CSF) is poor.3 In vitro and in vivo studies have suggested that the brain distribution of several quinolones is restricted by the operation of multiple efflux transporters.4 Fluoroquinolones are known to cause central nervous system (CNS) adverse effects such as hallucinations and seizures.1 These effects are likely to be the result of excitation of N-methyl-Daspartate (NMDA) receptors and inhibition of gamma-aminobutyric acid (GABA-A) receptors.5 Myoclonus is a neurological sign described as involuntary and sudden contractions of a muscle or group of muscles affecting the arms, legs, face, neck or other parts of the body, resulting in twitches or jerks. It can result in debilitating impairment for which specific treatment is needed.6,7 Myoclonus is associated with a wide range of clinical conditions and can be of cortical, subcortical or spinal origin. There is therefore no specific age range that is typically affected. It can occur with both focal nervous system damage and metabolic disorders including renal failure, electrolyte abnormalities and hypoxia. It can occur with epilepsy, peripheral motor neuropathy and encephalopathy, all of which are recognised adverse effects of fluoroquinolones.6,8 Published case reports and case series have implicated a range of medicines in the development of myoclonus, the most frequently reported being opiates, antidepressants, antipsychotics and antibiotics including beta-lactams and fluoroquinolones.9 Three published case reports have been found for levofloxacin, all involving older patients.5 We assessed the reports in VigiBase for causality and to assess the evidence for the hypotheses that (1) nervous system co-morbidities, and (2) increasing renal impairment leading to higher levofloxacin blood levels and potentially greater CNS penetration, might have contributed to the disproportionate reporting in the elderly." ;
              rdfs:label "introduction" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#lansoprazole
:lansoprazole rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A02BC03" ,
                                                                           "A02BC53" ,
                                                                           "A02BD02" ,
                                                                           "A02BD03" ,
                                                                           "A02BD07" ,
                                                                           "A02BD09" ,
                                                                           "A02BD10" ;
              rdfs:label "lansoprazole" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#levofloxacin_intake_form
:levofloxacin_intake_form rdf:type owl:NamedIndividual ,
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Intake_Form> ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Levofloxacin ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_form_of_intake> "oral" ;
                          rdfs:label "levofloxacin oral intake form" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#levofloxacin_interval_administration
:levofloxacin_interval_administration rdf:type owl:NamedIndividual ,
                                               <http://www.w3.org/2006/time#DurationDescription> ;
                                      <http://www.w3.org/2006/time#nominalPosition> "days" ;
                                      <http://www.w3.org/2006/time#numericPosition> 1 ;
                                      rdfs:label "levofloxacin interval administration" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#levofloxacin_intravenous_intake_form
:levofloxacin_intravenous_intake_form rdf:type owl:NamedIndividual ,
                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Intake_Form> ;
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Levofloxacin ;
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_form_of_intake> "injected (intraveneous)" ;
                                      rdfs:label "levofloxacin intravenous intake form" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#memantine
:memantine rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_mechanism> :Other_possible_mechanism_of_myoclonus ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N06DA52" ,
                                                                        "N06DA53" ,
                                                                        "N06DX01" ;
           rdfs:label "memantine" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#metoclopramide
:metoclopramide rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A03FA01" ;
                rdfs:label "metoclopramide" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#nadolol
:nadolol rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C07AA12" ,
                                                                      "C07BA12" ;
         rdfs:label "nadolol" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#paracetamol
:paracetamol rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N02BE01" ;
             rdfs:label "paracetamol" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#phychosis
:phychosis rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "F29" ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10037234 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Psychosis" ;
           rdfs:label "psychosis" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#pneumonia
:pneumonia rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "J15.8" ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10035664 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Pneumonia" ;
           rdfs:label "Pneumonia" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#pulmonaryTuberculosis
:pulmonaryTuberculosis rdf:type owl:NamedIndividual ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "A15.3" ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10037440 ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Pulmonary tuberculosis" ;
                       rdfs:label "Pulmonary tuberculosis" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#pyelonephritis
:pyelonephritis rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "N12" ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10037596 ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Pyelonephritis" ;
                rdfs:label "pyelonephritis" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#renal_failure
:renal_failure rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10038435 ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Renal failure" ;
               rdfs:label "renal failure" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#reports_with_dosage_info
:reports_with_dosage_info rdf:type owl:NamedIndividual ,
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_reported_drug_usage> :Levofloxacin_usage_in_reports ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 17 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                          rdfs:label "reports with dosage info" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#reports_with_encephalopathy
:reports_with_encephalopathy rdf:type owl:NamedIndividual ,
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_unconfirmed_adverse_effect> :Encephalopathy ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 3 ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                             rdfs:label "reports with encephalopathy" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#reports_with_gabapentin
:reports_with_gabapentin rdf:type owl:NamedIndividual ,
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :gabapentin ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                         rdfs:label "reports with gabapentin" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#reports_with_positive_rechallenge
:reports_with_positive_rechallenge rdf:type owl:NamedIndividual ,
                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_rechallenge_outcome> "positive rechallenge - condition appeared again" ;
                                   rdfs:label "reports with positive rechallenge" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#rifampicin
:rifampicin rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "J04AB02" ;
            rdfs:label "rifampicin" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#serotonin_syndrome
:serotonin_syndrome rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10040108 ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Serotonin syndrome" ;
                    rdfs:label "serotonin syndrome" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#summary
:summary rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Summary> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Signal detection focusing on subgroups in VigiBase, the WHO global database of individual case safety reports (ICSRs), identified disproportionate reporting of the combination levofloxacin and myoclonus only in patients aged over 75 years. Product labels for levofloxacin do not list myoclonus as an adverse reaction and indicate that the listed central nervous system adverse effects are not confined to the elderly. Dose adjustments are recommended for levofloxacin in patients with renal impairment as it primarily undergoes renal excretion as the unchanged drug. Assessment of the 20 reports indicated that levofloxacin was the most likely cause of myoclonus in the majority of the cases. Co-reported central nervous system adverse effects included encephalopathy and seizures. Five patients had renal impairment with clear evidence of dose adjustment in one. There was a high prevalence of cerebral and metabolic disorders likely to predispose to myoclonus. In contrast, renal impairment and cerebral disorders were not prominent features in the 18 reports for patients aged under 75 years, which might explain why disproportionate reporting of the combination was confined to the elderly. Medicines that may also cause myoclonus were co-prescribed in 40% of the older group compared with 33% of younger patients and so were less likely to account for the observed age difference in reporting. Most of these medicines can also lower the seizure threshold, and product labels caution about the use of such medicines with levofloxacin. Reports of levofloxacin and myoclonus support a causal relationship for levofloxacin and myoclonus and indicate some possible reasons why the elderly may be more often affected. The reports also provide reminders to monitor renal function and adjust the levofloxacin dose accordingly, and to avoid, where possible, co-prescription of medicines with levofloxacin that can also induce myoclonus and lower the seizure threshold." ;
         rdfs:label "summary" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#urapidil
:urapidil rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C02CA06" ;
          rdfs:label "urapidil" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#urinaryTractInfections
:urinaryTractInfections rdf:type owl:NamedIndividual ,
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "N39.0 " ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10046571 ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> """Urinary tract infection
""" ;
                        rdfs:label "Urinary tract infection" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#2011_review
<http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#2011_review> rdf:type owl:NamedIndividual ,
                                                                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Literature_information> ;
                                                                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_part_of> :Literature_and_Labelling ;
                                                                                     mp:references :Ref.12 ;
                                                                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """\"In 2011, a review was published of psychiatric and
neurological adverse reactions attributed to
fluoroquinolones, identified through published case
reports and case series.12 Out of the total of 206
adverse reactions, convulsions were most
frequently reported. There were six reports of
myoclonus, none attributed to levofloxacin. The
authors also noted that fluoroquinolone CSF
penetration can increase with meningeal
inflammation. Levofloxacin is listed as one of the
least likely of the fluoroquinolones to cause CNS
adverse effects because of low CSF penetration.
Although, at the time of the study, ciprofloxacin
and levofloxacin were the most widely marketed  fluoroquinolones, only 10 adverse reactions
attributed to levofloxacin were identified. These
included grand mal convulsions (3) and delirium
(2).\"""" ;
                                                                                     rdfs:label "2011 review" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Amoxicillin/clavulanicAcid
<http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Amoxicillin/clavulanicAcid> rdf:type owl:NamedIndividual ;
                                                                                                    rdfs:label "Amoxicillin/clavulanicAcid" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Levofloxacin_and_myoclonus_in_the_elderly_over_75_years:_susceptibilities_and_prescribing_issues
:Levofloxacin_and_myoclonus_in_the_elderly_over_75_years:_susceptibilities_and_prescribing_issues rdf:type owl:NamedIndividual ,
                                                                                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Pharmacovigilance_Signal_Report> ;
                                                                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_author> :Savage_Ruth ,
                                                                                                                                                                   :Zappacosta_Sofia ;
                                                                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_signal> :PV_signal_referring_to_Levofloxacin_and_myoclonus_in_the_elderly_over_75_years:_susceptibilities_and_prescribing_issues ;
                                                                                                  mp:publishedBy :Upsalla_Monitoring_Centre ;
                                                                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_creation_date> "1/3/2019"^^xsd:date ;
                                                                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_overall_conclusion> "causal association" ;
                                                                                                  rdfs:label "Levofloxacin and myoclonus in the elderly over 75 years: susceptibilities and prescribing issues" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#PV_signal_referring_to_Levofloxacin_and_myoclonus_in_the_elderly_over_75_years:_susceptibilities_and_prescribing_issues
:PV_signal_referring_to_Levofloxacin_and_myoclonus_in_the_elderly_over_75_years:_susceptibilities_and_prescribing_issues rdf:type owl:NamedIndividual ,
                                                                                                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Signal> ;
                                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element> :Myoclonus_as_ADR ,
                                                                                                                                                                                                     :Reports_in_VigiBase ,
                                                                                                                                                                                                     :conclusion ,
                                                                                                                                                                                                     :introduction ,
                                                                                                                                                                                                     :summary ;
                                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_supported_by_individual_case_report> :Report1 ,
                                                                                                                                                                                                                :Report10 ,
                                                                                                                                                                                                                :Report11 ,
                                                                                                                                                                                                                :Report2 ,
                                                                                                                                                                                                                :Report3 ,
                                                                                                                                                                                                                :Report4 ,
                                                                                                                                                                                                                :Report5 ,
                                                                                                                                                                                                                :Report6 ,
                                                                                                                                                                                                                :Report7 ,
                                                                                                                                                                                                                :Report8 ,
                                                                                                                                                                                                                :Report9 ;
                                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_supported_by_statistical_entity> :IC005_for_levofloxacin_and_myoclonus_for_the_elderly ,
                                                                                                                                                                                                            :IC_for_levofloxacin_and_myoclonus_for_the_elderly ,
                                                                                                                                                                                                            :OverallReportsInVigibase ,
                                                                                                                                                                                                            :ReportsDechallengedHavingRecoveryAsOutcome ,
                                                                                                                                                                                                            :ReportsInVigibaseForCasesLessThan75 ,
                                                                                                                                                                                                            :ReportsInVigibaseForCasesOver75 ,
                                                                                                                                                                                                            :ReportsInVigibaseInWhichAgeIsMentioned ,
                                                                                                                                                                                                            :ReportsInWhichLevofloxacinWasTheOnlySuspectDrug ,
                                                                                                                                                                                                            :ReportsWithAnOnsetWithin16Days ,
                                                                                                                                                                                                            :ReportsWithIntravenousAdministration ,
                                                                                                                                                                                                            :ReportsWithLessThanAWeekOfOnset ,
                                                                                                                                                                                                            :ReportsWithOralAdministration ,
                                                                                                                                                                                                            :ReportsWithRenalImpairment ,
                                                                                                                                                                                                            :reports_with_dosage_info ,
                                                                                                                                                                                                            :reports_with_encephalopathy ,
                                                                                                                                                                                                            :reports_with_gabapentin ,
                                                                                                                                                                                                            :reports_with_positive_rechallenge ;
                                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Levofloxacin ;
                                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Levofloxacin ;
                                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_unconfirmed_adverse_effect> :Myoclonus ;
                                                                                                                         mp:supportedByData :BlackBoxWarningForFluoroquinolones ,
                                                                                                                                            :Decreasing_the_seizure_threshold ,
                                                                                                                                            :LevofloxacinAndCNSReactions ,
                                                                                                                                            :Review_for_fluoroquinolones_and_psychiatric_and_neurological ,
                                                                                                                                            :Seizures_and_levofloxacin ,
                                                                                                                                            :US_FDA_Black_Box_Warning_for_fluoroquinolones ;
                                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#initially_identified_on> "1/3/2019" ;
                                                                                                                         rdfs:label "PV signal referring to Levofloxacin and myoclonus in the elderly over 75 years: susceptibilities and prescribing issues" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Parkinson's_disease
<http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#Parkinson's_disease> rdf:type owl:NamedIndividual ,
                                                                                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Potential_Confounder> ;
                                                                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "G20" ;
                                                                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10061536 ;
                                                                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Parkinson's disease" ;
                                                                                             rdfs:label "Parkinson's disease" .


###  http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#cerebralarteriosclerosis,Epilepsy
<http://purl.org/OpenPVSignal/Signals/2019_1_levofloxacin_myoclonus.owl#cerebralarteriosclerosis,Epilepsy> rdf:type owl:NamedIndividual ;
                                                                                                           rdfs:label "cerebralarteriosclerosis,Epilepsy" .


#################################################################
#    Annotations
#################################################################

:conclusion rdfs:label "conclusion" .


###  Generated by the OWL API (version 4.5.9.2019-02-01T07:24:44Z) https://github.com/owlcs/owlapi
